JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN
Journal of Clinical Oncology (JCO) Podcast
Release Date: 10/27/2025
Milan Consensus Endpoints for Bladder Preservation in MIBC
Journal of Clinical Oncology (JCO) Podcast
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article ",” focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your...
info_outline
JCO at 2025 ASH: Pirtobrutinib in Untreated CLL
Journal of Clinical Oncology (JCO) Podcast
JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I’m Jonathan Friedberg, editor of , and welcome to , where we are covering two manuscripts that were presented at the meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on...
info_outline
JCO at ASH 2025: A New Validated Staging System for AL Amyloidosis: AL-ISS
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Peter Li and author Dr. Jahanzaib Khwaja discuss the ASH 2025 Simultaneous Publication article, "." TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO’s Editorial Fellow, and today, I am joined by Dr. Jahanzaib Khwaja on . This is a simultaneous publication that will be presented at this year’s ASH Conference. At the time of this recording, our guest has disclosures that will be linked in the transcript. So, Dr. Khwaja, let’s...
info_outline
JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "" by Bradley, et al published October 13, 2025. TRANSCRIPT Dr. Ece Cali: Welcome to this episode of . This is Dr. Ece Cali, Editorial Fellow. Today I'm joined by Dr. Jeffrey Bradley, Professor of Radiation Oncology at the University of Pennsylvania, to discuss the manuscript, "" The PACIFIC-2 study was a phase III, double-blind, randomized trial comparing the efficacy and safety of simultaneous durvalumab with concurrent chemoradiation followed by consolidation...
info_outline
Health Outcomes in Older Childhood Cancer Survivors
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. Rusha Bhandari and host Dr. Davide Soldato discuss JCO article "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, " with a particular focus on mortality data, development of secondary malignancies and the importance of education for both patients and healthcare providers regarding long-term follow-up and care. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to , the podcast where we sit down with authors from some of the latest articles...
info_outline
Long-Term Remission After Cilta-cel in Patients With RRMM
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in . I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer...
info_outline
JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Lauren Shih summarizes the article, "" by Bourhis, et al published September 03, 2025 TRANSCRIPT
info_outline
Income Among Adolescents and Young Adults Surviving Cancer
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Shannon Westin and guest Dr. Giancarlo Di Guiseppe discuss the JCO article "" TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hi everybody and welcome to another episode of , the podcast where we go in depth on manuscripts that are published in the . I'm your host, Dr. Shannon Westin, social media editor of and gynecologic oncologist extraordinaire. I'm so very excited to talk to you today. We're going to speak about "." And I'm joined today by Dr. Giancarlo Di Giuseppe. He has a PhD in epidemiology that he actually just defended...
info_outline
JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs
Journal of Clinical Oncology (JCO) Podcast
In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript. Dr. Ece Cali: Welcome to this episode of . This is Dr. Ece Cali, editorial fellow, and today I am joined by Dr. Martin Wermke, Professor for Experimental Cancer Therapy at Dresden University of Technology, to discuss the manuscript “.” Obrixtamig is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T-cells. This manuscript presents the phase 1A dose escalation results...
info_outline
TTFields in Locally Advanced Pancreatic Adenocarcinoma
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "" TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of , the podcast where we get in depth with manuscripts that have been published in the . I am your host, gynecologic oncologist , social media editor at the JCO, and just excited to be here to learn today about pancreatic cancer. None of our participants have conflicts of interest related to this podcast, and it is my honor to introduce . He is an associate professor of medicine,...
info_outlineIn this episode of JCO Article Insights, host Dr. Lauren Shih summarizes the article, "Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study" by Bourhis, et al published September 03, 2025
TRANSCRIPT